Call Us: 1.800.873.5297

By

Mirena® IUD Lawsuit Update: 36 New Lawsuits Filed in Federal Multidistrict Litigation (MDL 2434)

The number of Mirena® lawsuits continues to grow with 159 lawsuits currently on file in federal court in the Multidistrict Litigation In re: Mirena® IUD Products Liability Litigation (MDL 2434), according to the most recent report issued by the Judicial Panel on Multidistrict Litigation (JPML). The Mirena® MDL is pending in the United States District Court for the Southern District of New York before The Honorable Judge Cathy Seibel.

Mirena® is an intrauterine device (IUD) manufactured by Bayer Pharmaceuticals. The device is a t-shaped IUD which is inserted into a woman’s uterus and serves as a pregnancy prevention method – for up to five years. The device releases the hormone levonorgestrel – a third generation progestin – into the uterus to prevent the release of eggs from a woman’s ovaries. Generally, plaintiffs allege that the Mirena® IUD migrates from its original position in a woman’s body and causes serious injuries, such as uterine perforation, ectopic pregnancies, infertility, embedment of the device in the uterine wall or other organs, migration of the IUD, serious infections, and surgical removal of the device. Plaintiffs also allege that the product manufacturer failed to adequately warn women of the serious risks associated with the Mirena® IUD.

Since Mirena® was approved by the FDA in 2000, FDA records indicate that the agency has received over 50,000 complaints from women and health care providers reporting Mirena® IUD complications. In particular, FDA has received at least 5,000 reports involving women who indicated that Mirena® migrated out of place since 2008 and 1,322 reports where the Mirena® IUD punctured the uterus.

In 2010, the FDA issued a Warning Letter objecting to Bayer’s marketing campaign and informing Bayer that the company was downplaying the health risks of the Mirena® IUD, while overstating the benefits of the Mirena® IUD. In particular, the FDA said the “program overstates the efficacy of Mirena®, presents unsubstantiated claims, minimizes the risks of using Mirena®, and includes false or misleading presentations regarding Mirena®.” The FDA also directed Bayer to change the “side effects” portion of the Mirena® IUD product label in order to warn women of additional side effects associated with the Mirena® IUD. The new warning label now includes language indicating that use can be associated with serious health problems, such as congenital anomalies, embedment, perforation, expulsion, ovarian cysts and breast cancer.

 

Legal Disclaimer: The choice of a lawyer is an important decision and should not be based solely on advertisements.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.